Detecting EGFR alterations in clinical specimens - Pitfalls and necessities

Virchows Archiv

Volumn 463, Issue 6, 2013, Pages 755-764

  Isaksson, Sofi ^a   Bendahl, Pär Ola ^a   Salomonsson, Annette ^a   Jönsson, Mats ^a   Haglund, Monica ^a,b   Gaber, Alexander ^a,b   Jirström, Karin ^a,b   Jönsson, Per ^b   Borg, Åke ^a   Johansson, Leif ^a,b   Staaf, Johan ^a   Planck, Maria ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

EGFR; Gene copy number; Immunohistochemistry; Intratumoral heterogeneity; Lung cancer; Mutation specific antibody; Tissue microarray

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SWEDEN; TISSUE SECTION; VERY ELDERLY; CARCINOMA; GENETICS; LUNG TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROCEDURES; PROTO ONCOGENE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84890549671     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1489-y     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29. doi: 10.3322/caac.20138
3. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR (2004) The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10:4227s-4232s. doi: 10.1158/1078-0432.CCR-04000710/12/4227S
4. Hirsch FR, Herbst RS, Olsen C et al (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351-3357
5. Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717-723. doi: 10.1093/annonc/mdm492
6. Chung CH, Ely K, McGavran L et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170-4176. doi: 10.1200/jco.2006.07.2587
7. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M (2006) EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028-1029. doi: 10.1093/annonc/mdj114
8. Gwak GY, Yoon JH, Shin CM et al (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131:649-652. doi: 10.1007/s00432-005-0016-1
9. Schilder RJ, Sill MW, Chen X et al (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clin Cancer Res 11:5539-5548. doi: 10.1158/1078-0432.CCR-05-0462
10. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883. doi: 10.1056/NEJM200412303512724
11. Lee JW, Soung YH, Kim SY et al (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879-2882. doi: 10.1158/1078-0432.CCR-04-2029
12. Kwak EL, Jankowski J, Thayer SP et al (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287. doi: 10.1158/1078-0432.CCR-06-0189
13. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181
14. Califano R, Landi L, Cappuzzo F (2012) Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 72:28-36. doi: 10.2165/1163012-S1163010-000000000-000000000
15. Hirsch FR, Varella-Garcia M, Cappuzzo F et al (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18:752-760. doi: 10.1093/annonc/mdm003
16. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144. doi: 10.1056/NEJMoa050736
17. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957. doi: 10.1056/NEJMoa0810699
18. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology 13:239-246
19. Kawahara A, Yamamoto C, Nakashima K et al (2010) Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16:3163-3170. doi: 10.1158/1078-0432.CCR-09-3239
20. Yu J, Kane S, Wu J et al (2009) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15:3023-3028. doi: 10.1158/1078-0432.CCR-08-2739
21. Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12:169-176. doi: 10.2353/jmoldx.2010.090140
22. Varella-Garcia M (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1:19
23. Ilie MI, Hofman V, Bonnetaud C et al (2010) Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 457:483-495. doi: 10.1007/s00428-010-0963-z
24. Wu S-G, Chang Y-L, Lin J-W et al (2011) Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE 6:e23303. doi: 10.1371/journal.pone. 0023303
25. Karlsson C, Bodin L, Piehl-Aulin K, Karlsson MG (2009) Tissue microarray validation: a methodologic study with special reference to lung cancer. Cancer Epidemiol Biomarkers Prev 18:2014-2021. doi: 10.1158/1055-9965.epi-08-0743
26. Nitadori J, Ishii G, Tsuta K et al (2006) Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol 125:682-692. doi: 10.1309/DT6B-J698-LDX2-NGGX
27. Zheng H, Saito H, Masuda S, Yang X, Takano Y (2007) Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res 27:3561-3569
28. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y (2010) Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 16:3349-3355. doi: 10.1158/1078-0432.ccr-10-0129
29. Yatabe Y, Matsuo K, Mitsudomi T (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972-2977. doi: 10.1200/jco.2010.33.3906
30. Mattsson JSM, Imgenberg-Kreuz J, Edlund K, Botling J, Micke P (2012) Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology. doi: 10.1111/j.1365-2559.2012.04245.x
31. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99:929-935. doi: 10.1111/j.1349-7006.2008.00782.x
32. Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II (2008) Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Canc Prev Res 1:192-200. doi: 10.1158/1940-6207.capr-08-0032
33. Dimou A, Agarwal S, Anagnostou V et al (2011) Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 179:580-589
34. Kato Y, Peled N, Wynes MW et al (2010) Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5:1551-1558
35. Simonetti S, Molina MA, Queralt C et al (2010) Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 8:135. doi: 10.1186/1479-5876-8-135
36. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346. doi: 10.1093/jnci/dji055
37. Kozu Y, Tsuta K, Kohno T et al (2011) The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands) 73:45-50
38. Angulo B, Conde E, Suárez-Gauthier A et al (2012) A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS ONE 7:e43842. doi: 10.1371/journal.pone. 0043842
39. Meert AP, Martin B, Delmotte P et al (2002) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20:975-981
40. Jeon YK, Sung SW, Chung JH, Park WS, Seo JW, Kim CW, Chung DH (2006) Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54:387-398. doi: 10.1016/j.lungcan.2006.08.015
41. Liu H-P, Isaac Wu H-D, Chang JW-C et al (2010) Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in taiwan. J Thorac Oncol 5:1175-1184
42. Marks JL, Broderick S, Zhou Q et al (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3:111-116
43. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res 64:8919-8923. doi: 10.1158/0008-5472.can-04-2818
44. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4:22-29. doi: 10.1097/JTO.1090b1013e3181914111